The CDG asks for your consent: We would like to process your pseudonymised data about the use of the website for analysis purposes in order to understand how visitors use our website so that we can make it even better and more intuitive. We use the open-source software Matomo for this purpose. By clicking on "accept all" you can give us your consent for this. You can revoke your consent at any time with effect for the future. You can withdraw your consent at any time by clicking the button "Customise cookie settings" and unchecking the "Analyse" box. The legality of the processing carried out up to that point is not affected by the cancellation.
Without your consent, we will only process your data to the extent technically necessary to display the website to you. Information on the required data processing and the technically required cookies can be found after clicking on the "Settings" button under "Required cookies" and in our privacy policy.
The focus is on innovative analyses of biological sample material that will contribute to the characterisation and effective collection of such samples in so-called biobanks. Indicators for certain diseases (biomarkers), which contribute to the optimisation of personalised therapies, are a focal point.
Cells, tissue and body fluids contain information about genetic and non-genetic causes of diseases as well as factors that influence the course of diseases. In order to access this information, the possibilities of the latest DNA sequencing technologies are being utilised in the service of molecular pathology. However, not all information is contained in the genes. For this reason, research is also being conducted into technologies that contribute to a detailed characterisation of the entire metabolism (metabolome) of a cell or tissue.
The development and testing of new technologies for the collection and preservation of biological sample material is of particular interest. In particular, these should allow the metabolome to be analysed using Nuclear Magnetic Resonance Spectroscopy (NMR) or the entire genome of a sample to be analysed (metagenome study).
The stabilisation of biological samples is also being further developed. In future, it should be possible to analyse samples using several different methods without the need for further sample processing. A specially developed method, PAXgene fixation, will open up pioneering possibilities.
Another focus of special interest is the establishment of a robust and simple pre-analytical work process that allows the reliable analysis of medium- to high-risk pathogens in tissues.
Overall, the activity serves the goal of using new biomarkers for personalised Medicine. This is because the personalisation of therapies - i.e. tailoring them to the individual physiological and genetic requirements of individual patients - offers numerous opportunities for increasingly effective forms of treatment. The key to such personalisation of Medicine therapies is often hidden in biological samples. Indeed, in the past, efficient access to high-quality biological samples has proven to be one of the limiting factors in most areas of academic and industrial biomedical research. The work carried out here will make an important contribution to removing this limitation.
Christian Doppler Forschungsgesellschaft
Boltzmanngasse 20/1/3 | 1090 Wien | Tel: +43 1 5042205 | Fax: +43 1 5042205-20 | office@cdg.ac.at
© 2020 Christian Doppler Forschungsgesellschaft